ENLV ▼ -3.8% - Enlivex Ltd.
$ENLV - Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
02-NOV-2026 08:00 AM ET
Share this post
More filings for $ENLV
ENLV ▲ +4.4% - Enlivex Ltd.Oct 28, 2026ENLV ▲ +6.3% - Enlivex Ltd.Oct 27, 2026ENLV ▼ -10.0% - Enlivex Ltd.Oct 22, 2026
View full $ENLV filing history →💬 Comments
Loading comments…
Leave a comment